VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome

VolitionRx Ltd. has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center to evaluate antiphospholipid syndrome (APS) using Volition's proprietary Nu.Q H3.1 Neutrophil Extracellular Traps (NETs) assay on Werfen diagnostic platforms. This collaboration represents a significant step in advancing diagnostic capabilities for APS, a complex autoimmune disorder affecting approximately 4 million people globally.

The partnership leverages Werfen's expertise in specialized diagnostics and its installed base of proprietary analyzers, including the ACL AcuStar platform where the Nu.Q NETs assay has already been successfully transferred. Early results in detecting NETs levels in APS patients have shown promising outcomes, suggesting potential improvements in both diagnostic decision-making and ongoing patient monitoring for this challenging condition.

Gael Forterre, Chief Commercial Officer at Volition, emphasized the strategic importance of this agreement, stating that it aligns with the company's approach to license its proprietary technology to established global companies that possess deep disease knowledge, product development capabilities, and regulatory experience. The collaboration aims to validate the clinical utility of the Nu.Q NETs assay as a risk indicator for thrombosis in APS patients, potentially enabling better management of this complex syndrome.

Marta Palicio, Werfen's Immunoassay Technology Center Innovation R&D Director, expressed enthusiasm about the partnership's potential to expand Werfen's portfolio in APS testing. Current APS diagnosis typically requires two positive antibody tests conducted at least 12 weeks apart, making the development of more efficient diagnostic tools particularly valuable for both patients and healthcare providers.

Volition believes its Nu.Q NETs test represents the first CE-IVD biomarker being investigated specifically for APS applications. The successful implementation of this technology could lead to earlier detection and improved monitoring of the disease, potentially enhancing patient outcomes and quality of life for those affected by this autoimmune disorder. For additional information about Volition's technology and research initiatives, visit https://www.Volition.com.